Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of five botulinum toxin A products for masseter bite force reduction and upper-face wrinkle treatment
TCTR20211205001Phase 4Completed
- Sponsor
- Siriraj Hospital
- Start
- Oct 2021
- Modality
- Recombinant Proteins and Enzymes, Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of botulinum toxin type A and letibotulinumtoxinA in masseter hypertrophy and Rhytidosis facialis (5 arms), sponsored by Siriraj Hospital. Primary endpoints: Bite force at 6 months, Wrinkle improvement scale at 6 months and 2 more. Started Oct 2021; status: completed.
02
Drugs
botulinum toxin type AletibotulinumtoxinA
03
Conditions
masseter hypertrophyRhytidosis facialis
Beyond the preview
Go deeper on TCTR20211205001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20211205001.